115 related articles for article (PubMed ID: 26597477)
1. [Non-small cell lung cancer: Remarkable developments].
Vignot S; Wislez M
Bull Cancer; 2015 Dec; 102(12):962-3. PubMed ID: 26597477
[No Abstract] [Full Text] [Related]
2. Ceritinib versus chemotherapy in ALK-positive lung cancer.
Marshall H
Lancet Respir Med; 2016 Dec; 4(12):952-953. PubMed ID: 27838332
[No Abstract] [Full Text] [Related]
3. American Society of Clinical Oncology Annual Meeting 2013.
Yaqub F
Lancet Respir Med; 2013 Jul; 1(5):360-1. PubMed ID: 24429195
[No Abstract] [Full Text] [Related]
4. Ceritinib (Zykadia) for non-small cell lung cancer.
Med Lett Drugs Ther; 2014 Jul; 56(1447):62-3. PubMed ID: 25046419
[No Abstract] [Full Text] [Related]
5. A Long-Term Spinal Intramedullary Response to Ceritinib in ALK Rearranged Non-Small-Cell Lung Cancer.
Biya J; Caramella C; Lindsay CR; Planchard D; Besse B
J Thorac Oncol; 2015 Jun; 10(6):e44-5. PubMed ID: 26001149
[TBL] [Abstract][Full Text] [Related]
6. Ceritinib (LDK378): a potent alternative to crizotinib for ALK-rearranged non-small-cell lung cancer.
Li S; Qi X; Huang Y; Liu D; Zhou F; Zhou C
Clin Lung Cancer; 2015 Mar; 16(2):86-91. PubMed ID: 25458559
[TBL] [Abstract][Full Text] [Related]
7. HER2/neu intragenic kinase domain mutations may be major determinant of response to trastuzumab or specific kinase inhibitors in non-small cell lung cancer patients.
Altundag O; Altundag K; Ozcakar B; Silay YS
Lung Cancer; 2005 Aug; 49(2):279-80. PubMed ID: 16022924
[No Abstract] [Full Text] [Related]
8. Antiangiogenic agents as second-line therapy for advanced non-small cell lung cancer.
Reckamp KL
Cancer Lett; 2012 Aug; 321(2):101-9. PubMed ID: 22306704
[TBL] [Abstract][Full Text] [Related]
9. Editorial: Comparative efficacy and cost associated with new agents in the treatment of non-small cell lung cancer (NSCLC).
Mueller E
Lung Cancer; 2010 Aug; 69 Suppl 1():S1-3. PubMed ID: 20727456
[No Abstract] [Full Text] [Related]
10. [Pharmaceuticals can be cost-effective in the long run].
Jönsson B; Wilking N
Lakartidningen; 2010 Apr 21-27; 107(16):1081-5. PubMed ID: 20476706
[No Abstract] [Full Text] [Related]
11. Targeted agents in non-small cell lung cancer (NSCLC): clinical developments and rationale for the combination with thoracic radiotherapy.
Koh PK; Faivre-Finn C; Blackhall FH; De Ruysscher D
Cancer Treat Rev; 2012 Oct; 38(6):626-40. PubMed ID: 22196919
[TBL] [Abstract][Full Text] [Related]
12. [Personalized, targeted treatment of non-small cell lung cancer].
Wolf J
Dtsch Med Wochenschr; 2011 Mar; 136(10):480-5. PubMed ID: 21365525
[No Abstract] [Full Text] [Related]
13. First-line treatment for advanced nonsmall cell lung cancer harboring activating epidermal growth factor receptor mutation: epidermal growth factor receptor tyrosine kinase inhibitors or chemotherapy?
Gridelli C
Curr Opin Oncol; 2011 Mar; 23(2):131-2. PubMed ID: 21307676
[No Abstract] [Full Text] [Related]
14. Directed therapies in lung cancer: new hope?
Parente Lamelas I; Abal Arca J; Fírvida Pérez JL
Arch Bronconeumol; 2012 Oct; 48(10):367-71. PubMed ID: 22551924
[TBL] [Abstract][Full Text] [Related]
15. Targeted therapies in the treatment of advanced non-small-cell lung cancer: update.
Mendoza L
Klin Onkol; 2009; 22(4):131-8. PubMed ID: 19731875
[TBL] [Abstract][Full Text] [Related]
16. Multitargeted inhibitors in lung cancer: new clinical data.
Bar J; Herbst RS; Onn A
Clin Lung Cancer; 2008; 9 Suppl 3():S92-9. PubMed ID: 19419930
[TBL] [Abstract][Full Text] [Related]
17. Looking for a new panacea in ALK-rearranged NSCLC: may be Ceritinib?
Rolfo C; Passiglia F; Russo A; Pauwels P
Expert Opin Ther Targets; 2014 Sep; 18(9):983-5. PubMed ID: 24998601
[TBL] [Abstract][Full Text] [Related]
18. First-line therapeutic options for advanced non-small-cell lung cancer in the molecular medicine era.
Capelletto E; Novello S; Scagliotti GV
Future Oncol; 2014 May; 10(6):1081-93. PubMed ID: 24941991
[TBL] [Abstract][Full Text] [Related]
19. [Side effects of epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI)].
Takeda K
Nihon Rinsho; 2015 Feb; 73 Suppl 2():245-9. PubMed ID: 25831761
[No Abstract] [Full Text] [Related]
20. Re: How much is life worth: cetuximab, non-small cell lung cancer, and the $440 billion question.
Cohen J; Looney W
J Natl Cancer Inst; 2010 Aug; 102(15):1207; author reply 1207-10. PubMed ID: 20651322
[No Abstract] [Full Text] [Related]
[Next] [New Search]
